Antibiotic Prophylaxis, Breast Milk; Noxious Influence, Affecting Fetus, Dysbiosis, Neonatal Infection, Prenatal Exposure Delayed Effects
Conditions
Keywords
IgA, Prenatal antibiotics, breast milk, feces, neonatal immune system
Brief summary
In this biological study, the investigators will evaluate the levels of breast milk IgA, neonatal fecal IgA, and the composition of breast milk and fecal microbiota throughout the first 12 months of life in neonates born to mothers treated or not treated with prenatal antibiotics for at least 7 days after the 32nd weeks of gestation
Detailed description
In a human cohort of women and their neonates, the investigators aim to evaluate the absolute amount of IgA in maternal breast milk and in neonatal feces in the presence (N=41 mother/infant pairs) or in the absence (N=41 mother/infant pairs) of exposure to prenatal ABX during the last period of pregnancy. Moreover, the investigators aim to evaluate, both in maternal breast milk and in neonatal feces, the composition of microbiota, and the proportion and composition of the IgA-coated and not-IgA- coated fractions of microbiota, by means of fluorescence-activated cell sorting (FACS) coupled with 16S rRNA sequencing of bacteria. Finally, the investigators will measure the concentration of the chemokine CCL28 on maternal serum and breast milk, as a soluble marker of activity of the entero-mammary pathway that is known to drive the migration of IgA producing plasma- cells from maternal mesenteric lymph nodes to the mammary gland. All the analysis will be performed in mother-infant dyads with exclusive breastfeeding. Breast milk/serum/feces collection and analysis will be repeated at the following timepoints: 1. during the first week of neonatal life 2. at 1 month of life 3. at 3 months of life 4. at 8-12 months of life (or at the time of breastfeeding interruption), after the introduction of solid food in the infant's diet.
Interventions
DRUGAntibiotics
Any antibiotic therapy administered \> 7 days
Sponsors
Humanitas Hospital, Italy
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 40 Years
Inclusion criteria
* expression of written informed consent * an antibiotic treatment (any molecule) for at least 7 days consecutively after the 32 weeks of pregnancy (or the absence of exposure to any systemic antibiotic treatment during pregnancy for the control group) * the intention to breastfeed their neonates as long as possible during the first year of life
Exclusion criteria
* absence of written informed consent * the intention to formula feed exclusively (or the presence of significant maternal concerns about breastfeeding) * a maternal antibiotic treatment shorter than 7 days * the presence of pre-existing maternal immune-mediated disorders (including immunodeficiencies and chronic infectious diseases) * a delivery at a gestational age \< 34 weeks * the administration of antibiotics to neonates after birth, within the first week of life.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| breast milk IgA | until 12 months of neonatal life | concentration of IgA in breast milk |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| fecal IgA | until 12 months of neonatal life | concentration of IgA in neonatal feces |
| breast milk microbiota | until 12 months of neonatal life | Composition of microbiota in breast milk and analysis of fractions coated or uncoated by IgA |
| fecal microbiota | until 12 months of neonatal life | Composition of microbiota in breast milk and analysis of fractions coated or uncoated by IgA |
| maternal CCL28 | until 12 months of neonatal life | concentration of CCL28 in maternal serum and breast milk |
Countries
Italy
Contacts
Primary ContactCarlo Pietrasanta, MD,PhD
Outcome results
None listed